Which factors render cost-covering lump-sum charging difficult for the treatment of patients with acute leukemias?

Onkologie

Volumn 24, Issue 3, 2001, Pages 292-294

  Kuse, R ^a   Colberg, H ^a   Marbe W ^b   Kodalle, O ^b   Kalmar P ^b   Lohfert, C ^b  

^a Hämatologische Abteilung   (Germany)

^b Institut für Funktionsanalyse im Gesundheitswesen GmbH   (Germany)

Author keywords

Acute myeloid leukemia; AR DRG Classification; Australian Diagnosis Related Groups; Process cost analysis

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; DIAGNOSIS-RELATED GROUPS; FEMALE; GERMANY; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS;

EID: 0034927427     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055095     Document Type: Article

References (0)